Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Crizotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 11/20 | 1.00 |
| ▸ | ALK known ✓ | Q9UM73 | 7/20 | 1.00 |
| ▸ | ROS1 known ✓ | P08922 | 2/20 | 1.00 |
| ▸ | MST1R known ✓ | Q04912 | 2/20 | 1.00 |
| ▸ | NPM1 known ✓ | P06748 | 1/20 | 1.00 |
| ▸ | EML4 known ✓ | Q9HC35 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 7/20 | 1.00 |
| ▸ | MAP4K3 | Q8IVH8 | 7/20 | 1.00 |
| ▸ | JAK3 | P52333 | 4/20 | 1.00 |
| ▸ | JAK1 | P23458 | 3/20 | 1.00 |
| ▸ | TYK2 | P29597 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 2/20 | 1.00 |
| ▸ | INSR | P06213 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crizotinib SCHEMBL93829 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL94020 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29622387 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29831970 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL28844303 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL28844302 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29351506 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL30129754 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29831273 | 0.99 | MET (0.98) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL1827232 | 0.95 | MET (0.91) | METALKJAK2MAP4K3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4221706-B1 | TREATMENT FOR VIRAL INFECTION | UNIV OSLO HF (NO) | 2026-04-15 | — | — | EP | claimed |
| CN-118787639-A | Application of crizotinib and analogue and pharmaceutically acceptable salt thereof in preparation of drugs for treating iron death-related diseases | 重庆医科大学 | 2024-10-18 | — | — | CN | claimed |
| US-20240342153-A1 | TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION USING (S)-CRIZOTINIB | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2024-10-17 | — | — | US | claimed |
| EP-4433445-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INDUCING ANTIMICROBIAL INTRACELLULAR ACTIVITY AND FOR PREVENTING AND TREATING MICROBIAL INFECTIONS | The Broad Institute, Inc. (US) | 2024-09-25 | — | — | EP | claimed |
| US-20240294504-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INDUCING ANTIMICROBIAL INTRACELLULAR ACTIVITY AND FOR PREVENTING AND TREATING MICROBIAL INFECTIONS | THE BROAD INSTITUTE, INC. (US) | 2024-09-05 | — | — | US | claimed |
| CN-117883409-A | Medicine-carrying calcium-based nano generator wrapped by plant-derived exosomes, preparation method and anti-tumor application thereof | 中山大学·深圳 | 2024-04-16 | — | — | CN | claimed |
| WO-2023086671-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INDUCING ANTIMICROBIAL INTRACELLULAR ACTIVITY AND FOR PREVENTING AND TREATING MICROBIAL INFECTIONS | THE BROAD INSTITUTE, INC. (US) | 2023-05-19 | — | — | WO | claimed |
| WO-2023015197-A1 | TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION USING (S)-CRIZOTINIB | VANDA PHARMACEUTICALS INC. (US) | 2023-02-09 | — | — | WO | claimed |
| CN-112547019-B | Method for resolving racemic crizotinib | 上海工程技术大学 | 2022-12-20 | — | — | CN | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20160015702-A1 | AMINOHETEROARYL COMPOUNDS AS MTH1 INHIBITORS | CEMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH (AT) | 2016-01-21 | — | — | US | disclosed |
| EP-2892530-A1 | AMINOHETEROARYL COMPOUNDS AS MTH1 INHIBITORS | CeMM - FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH (AT) | 2015-07-15 | — | — | EP | disclosed |
| US-20140350050-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF KINASE | TELIGENE LTD (CN) | 2014-11-27 | — | — | US | disclosed |
| EP-2758387-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF KINASE | Teligene Ltd. (CN) | 2014-07-30 | — | — | EP | disclosed |
| WO-2014033136-A1 | AMINOHETEROARYL COMPOUNDS AS MTH1 INHIBITORS | CEMM - RESEARCH CENTER FOR MOLECULAR MEDICINE OF THE AUSTRIAN ACADEMY OF SCIENCES (AT) | 2014-03-06 | — | — | WO | disclosed |
| WO-2013041038-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF KINASE | TELIGENE LTD. (CN) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | MET 113/4885ALK 628/4885ROS1 1772/4885 |
| US-20240294504-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INDUCING ANTIMICROBIAL INTRACELLULAR ACTIVITY AND FOR PREVENTING AND TREATING MICROBIAL INFECTIONS | NFATC1, CTSA, PYCARD | MET 4241/4885ALK 4844/4885ROS1 406/4885 |
| US-20160015702-A1 | AMINOHETEROARYL COMPOUNDS AS MTH1 INHIBITORS | MTHFD1, NUDT15, NUDT1 | MET 1367/4885ALK 3500/4885ROS1 3716/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | MET 169/4885ALK 313/4885ROS1 2390/4885 |
| US-20240342153-A1 | TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION USING (S)-CRIZOTINIB | ACE2, TMPRSS2, ABL1 | MET 48/4885ALK 4/4885ROS1 33/4885 |
| US-20140350050-A1 | PYRIDINE COMPOUNDS AS INHIBITORS OF KINASE | MAP3K20, MAP3K1, MAP3K12 | MET 1068/4885ALK 34/4885ROS1 108/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | MET 4155/4885ALK 4644/4885ROS1 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.